

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035670 A2

- (51) International Patent Classification⁷: **C07K**
- (21) International Application Number: **PCT/US02/34208**
- (22) International Filing Date: 24 October 2002 (24.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/335,244 24 October 2001 (24.10.2001) US
- (71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MEHRABIAN, Margarete** [US/US]; University of California Los Angeles, Department of Medicine, 3-222 MRL, Los Angeles, CA 90095 (US). **ALLAYEE, Hooman** [US/US]; Department of Human Genetics, Gonda Genetics Research Center,, Room 6524, UCLA School of Medicine, 695 Charles young Dr. South, Los Angeles, CA 90095 (US). **LUSIS, Aldons, J.** [US/US]; University of California Los Angeles, Department of Medicine, 47-123 CHS, Los Angeles, CA 90095-1679 (US).
- (74) Agent: **SHERWOOD, Pamela, J.**; Bozicevic, Field & Francis LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF 5-LIPOXYGENASE AS A MAJOR GENE CONTRIBUTING TO ATHEROSCLEROSIS

(57) Abstract: 5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR-/- background, have dramatically reduced atherosclerosis as compared to control LDLR-/- mice. In a genetic epidemiologic study, it is found that a common 5-LO polymorphism is strongly associated with carotid artery intima-media thickness (IMT). These results indicate that 5-LO is a major contributor to atherogenesis in animal models, and in atherosclerosis susceptibility in humans.

BEST AVAILABLE COPY

WO 03/035670 A2

IDENTIFICATION OF 5-LIPOXYGENASE AS A MAJOR GENE CONTRIBUTING TO ATHEROSCLEROSIS

INTRODUCTION

5 Cardiovascular disease is a major health risk throughout the industrialized world. Atherosclerosis, the most prevalent of cardiovascular diseases, is the principal cause of heart attack, stroke, and gangrene of the extremities, and thereby the principle cause of death in the United States. Atherosclerosis is a complex disease involving many cell types and molecular factors. The process, in normal circumstances a protective response to
10 insults to the endothelium and smooth muscle cells (SMCs) of the wall of the artery, consists of the formation of fibrofatty and fibrous lesions or plaques, preceded and accompanied by inflammation. The advanced lesions of atherosclerosis may occlude the artery concerned, and result from an excessive inflammatory-fibroproliferative response to numerous different forms of insult. For example, shear stresses are thought to be
15 responsible for the frequent occurrence of atherosclerotic plaques in regions of the circulatory system where turbulent blood flow occurs, such as branch points and irregular structures.

The first observable event in the formation of an atherosclerotic plaque occurs when blood-borne monocytes adhere to the vascular endothelial layer and transmigrate through
20 to the sub-endothelial space. Adjacent endothelial cells at the same time produce oxidized low density lipoprotein (LDL). These oxidized LDL's are then taken up in large amounts by the monocytes through scavenger receptors expressed on their surfaces. In contrast to the regulated pathway by which native LDL (nLDL) is taken up by nLDL specific receptors, the scavenger pathway of uptake is not regulated by the monocytes.

25 These lipid-filled monocytes are called foam cells, and are the major constituent of the fatty streak. Interactions between foam cells and the endothelial and SMCs which surround them lead to a state of chronic local inflammation which can eventually lead to smooth muscle cell proliferation and migration, and the formation of a fibrous plaque. Such plaques occlude the blood vessel concerned and thus restrict the flow of blood, resulting in
30 ischemia.

Ischemia is a condition characterized by a lack of oxygen supply in tissues of organs due to inadequate perfusion. Such inadequate perfusion can have number of natural causes, including atherosclerotic or restenotic lesions, anemia, or stroke, to name a few. Many medical interventions, such as the interruption of the flow of blood during bypass
35 surgery, for example, also lead to ischemia. In addition to sometimes being caused by diseased cardiovascular tissue, ischemia may sometimes affect cardiovascular tissue, such

as in ischemic heart disease. Ischemia may occur in any organ, however, that is suffering a lack of oxygen supply.

The most common cause of ischemia in the heart is atherosclerotic disease of epicardial coronary arteries. By reducing the lumen of these vessels, atherosclerosis causes an absolute decrease in myocardial perfusion in the basal state or limits appropriate increases in perfusion when the demand for flow is augmented. Coronary blood flow can also be limited by arterial thrombi, spasm, and, rarely, coronary emboli, as well as by ostial narrowing due to luetic aortitis. Congenital abnormalities, such as anomalous origin of the left anterior descending coronary artery from the pulmonary artery, may cause myocardial ischemia and infarction in infancy, but this cause is very rare in adults. Myocardial ischemia can also occur if myocardial oxygen demands are abnormally increased, as in severe ventricular hypertrophy due to hypertension or aortic stenosis. The latter can be present with angina that is indistinguishable from that caused by coronary atherosclerosis. A reduction in the oxygen-carrying capacity of the blood, as in extremely severe anemia or in the presence of carboxy-hemoglobin, is a rare cause of myocardial ischemia. Not infrequently, two or more causes of ischemia will coexist, such as an increase in oxygen demand due to left ventricular hypertrophy and a reduction in oxygen supply secondary to coronary atherosclerosis.

Publications.

The sequence of human 5LO is reported by Dixon et al. (1988) Proc. Nat. Acad. Sci. 85: 416-42. Drazen et al. (1999) Nature Genetics 22:168-170 report a pharmacogenetic association between 5-LO promoter genotype and the response to anti-asthma treatment, which article is herein specifically incorporated by reference. In et al. (1997) J. Clin. Invest. 99:1130-1137 describe naturally occurring mutations in the human 5-LO gene promoter.

Lusis (2000) Nature 407:233-41 reviews atherosclerosis. Mehrabian et al. (2001) Circ Res 89:125-30 describes the positional mapping of a locus involved in susceptibility to atherosclerosis.

SUMMARY OF THE INVENTION

The present invention provides methods and compositions for the treatment and diagnosis of cardiovascular disease, including but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation; and also for the diagnosis of hyperglycemic conditions, including diabetes, insulin resistance, and the like. Specifically, the 5-lipoxygenase gene is identified as associated with a susceptibility to cardiovascular disease states. Alleles, including variations in the promoter region, are

associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to these conditions.

The invention also provides methods for the identification of compounds that modulate the expression of genes or the activity of gene products involved in cardiovascular disease, as well as methods for the treatment of cardiovascular disease, which may involve the administration of such compounds to individuals exhibiting cardiovascular disease symptoms or tendencies.

A major locus for susceptibility to atherosclerosis has been identified on mouse chromosome 6. This genetic locus provides almost complete resistance to atherogenesis despite extreme hyperlipidemia resulting from a deficiency of the low density lipoprotein receptor (LDLR^{-/-}). The gene encoding 5-lipoxygenase (5-LO) has been mapped to this region. 5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in animals resistant to atherogenesis when compared to susceptible animals.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B. Decreased 5-LO mRNA and protein levels in bone marrow cells from CON6 mice compared with B6 controls. A, Total bone marrow RNA was isolated from CON6/LDLR^{-/-} (n=3), 5LO +/- /LDLR^{-/-} (n=3), and LDLR^{-/-} (n=3) mice, and Northern analysis was performed using a cDNA probe to either 5-LO or GAPDH as a control. Levels of mRNA were quantitated by phosphorimaging and are expressed as the ratio of 5-LO to GAPDH. B, Immunoblot analysis of bone marrow homogenates from B6 (n=4) and CON6 (n=4) mice were performed using a specific commercially available rabbit anti-human 5-LO antibody (Cayman Chemical). Data are from 4- to 6-month-old mice on a chow diet and are representative of at least 3 experiments.

Figures 2A and 2B. Levels of LTB₄, LTA₄ hydrolase, and LTB₄ ω-hydroxylase in CON6 and B6 mice. A, LTB₄ levels in bone marrow cells of B6 (n=3) and CON6 (n=3) mice were determined by ELISA (Cayman Chemical). B, Levels of LTA₄ hydrolase and LTB₄ hydroxylase of B6 (n=3) and CON6 (n=3) were determined after immunoblot analysis using specific, commercially available antibodies (Cayman Chemical). Data are from 4- to 6-month-old animals on a chow diet and are representative of at least 3 experiments.

Figures 3A-3F. 5-LO is present in atherosclerotic lesions of apoE^{-/-} and LDLR^{-/-} mice. A through C, Staining of aortic sections with macrophage-specific MOMA-2 showed large advanced lesions. D through F, Adjacent proximal sections stained with anti-5-LO antibody showing colocalization of 5-LO (arrow) with a subset of macrophages surrounding the necrotic core (NC) but not with all regions staining for macrophages. A and D and B and E are from two 1-year-old apoE^{-/-} mice on a chow diet. C and F are representative of

lesions from a 4- to 6-month-old LDLR $-/-$ mouse on a high-fat, high-cholesterol diet for 8 weeks. I indicates intima; L, lumen; and M, media.

Figures 4A and 4B. Decreased 5-LO protein in macrophages from CON6 compared with B6 mice. Peritoneal monocyte/macrophage were isolated 3 days after thioglycolate treatment from 4- to 6-month-old CON6 (n=4) and B6 (n=4) mice on a chow diet. Cells were cultured overnight on glass slides and stained with a 5-LO-specific antibody and hematoxylin.

Figure 5. Decreased 5-LO protein in 5-LO $+/-$ /LDLR $-/-$ mice compared with LDLR $-/-$ controls. Immunoblot analysis of bone marrow cells stained with rabbit anti-human 5-LO antibody indicates that 5-LO $+/-$ /LDLR $-/-$ mice (n=3) have an approximately 90% reduction in 5-LO protein compared with control LDLR $-/-$ mice (n=3). Data are from 4- to 6-month-old animals on a chow or high-fat diet. Levels of 5-LO protein did not differ in LDLR $-/-$ mice on either a chow or high-fat (HF) diet.

Figures 6A and 6B. 5-LO-null mutation decreases aortic lesions even in the presence of elevated total cholesterol levels. Four- to six-month-old 5-LO $+/-$ (n=4) and 5-LO $+/+$ (n=4) mice on an LDLR $-/-$ background fed a high-fat, high-cholesterol diet for 8 weeks have over a 26-fold decrease in lesion formation, despite cholesterol levels that exceeded 500 mg/dL. There were no significant differences in the levels of LDL/VLDL-cholesterol.

Figure 7. Plasma insulin levels in 5-LO $+/-$ /LDLR $-/-$ mice compared with LDLR $-/-$ controls. Insulin levels from 4- to 6-month-old 5-LO $+/-$ /LDLR $-/-$ (n=5) and 5LO $+/+$ /LDLR $-/-$ (n=5) mice on a chow diet were determined by immunoassay as described in Materials and Methods. Mice fed a high-fat, high-cholesterol diet (n=5 for each genotype) had similar differences.

Figures 8A and 8B. LDLR $-/-$ mice transplanted with 5-LO $+/-$ bone marrow exhibit decreased 5-LO mRNA levels in bone marrow cells and have reduced atherosclerotic lesions. Four-month-old LDLR $-/-$ mice transplanted with either 5-LO $+/-$ /LDLR $-/-$ or LDLR $-/-$ bone marrow were allowed to recover for 4 weeks and then fed an atherogenic diet for 8 weeks. Nine mice of each genotype were examined for (A) levels of 5-LO mRNA from bone marrow cells by Northern blot analysis and (B) aortic lesions as described for Figure 6.

Figure 9 is a graph depicting the correlation of 5-LO promoter genotypes with insulin levels.

Figure 10 is a graph depicting the correlation of 5-LO genotypes with insulin resistance.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Methods and compositions for the diagnosis and treatment of cardiovascular disease, including but not limited to atherosclerosis, ischemia/reperfusion, hypertension,

restenosis, and arterial inflammation, are described. The invention is based, in part, on the evaluation of the expression and role of 5-LO, which is both differentially expressed in disease models, and for which alleles predisposing to atherogenesis are herein identified. This permits the definition of disease pathways and the identification of a target in the pathway that is useful both diagnostically, in drug screening, and therapeutically. Alleles of 5-LO that predispose to coronary artery disease (CAD) are also associated with insulin resistance and may be indicative of a predisposition to diabetes.

The leukotrienes constitute a group of arachidonic acid-derived compounds with biologic activities suggesting important roles in inflammation and immediate hypersensitivity. The enzyme 5-lipoxygenase (EC 1.13.11.34) catalyzes 2 reactions in the formation of leukotrienes. Matsumoto *et al.* (1988) Proc. Nat. Acad. Sci. 85:26-30, herein incorporated by reference, isolated cDNA clones for human lung and placenta 5-lipoxygenase and deduced the complete amino acid sequence of the enzyme.

Alleles of the human 5-LO gene have a promoter polymorphism, in which there is a variable number of tandem binding sites for the transcription factors Sp1/Egr-1 (Drazen *et al.* (1999) Nat Genet 22:168-70; and In *et al.* (1997) J. Clin. Invest. 99:1130-1137, herein incorporated by reference), where each repeat has the sequence motif GGGCGG. The common allele in the human population consists of five repeated binding sites and has been termed the "5", or "N" allele. Alleles with less than 5 repeats, usually 3 repeats or 4 repeats, may be referred to numerically as "3" or "4", or collectively as deleted, or "D" alleles. Alleles with expanded repeats greater than 5 in number, usually 6 or 7 repeats, may be referred to collectively as "E" expanded or "A" addition alleles. Four genotypic groups have been defined: homozygous 55 (indicating that both alleles consisted of five repeated binding sites); 33, 34, and 44 (one or two binding sites deleted); 35 and 45 (one allele deleted); and 56, 57, and 67 (one or both alleles expanded). A comparison between the genotypic groups revealed that individuals carrying deleted repeat alleles (genotypes 33, 34, or 44) had greatly increased incidence of coronary artery disease compared to individuals with either wild type alleles or larger numbers of repeats.

Predisposing 5-LO allele can have one or more Sp1/Egr-1 binding sites deleted, usually at least one binding site deletion on each chromosome, relative to the common allele in the human population, which wild type allele consists of five repeated Sp1/Egr-1 binding sites. Typically such susceptible alleles will have not more than 4 Sp1/Egr-1 binding site repeats. Other predisposing alleles are those changes in the 5-LO DNA sequence that confer an increased susceptibility to atherosclerosis.

In one aspect of the present invention, methods are provided for determining a predisposition to atherosclerosis in an individual. The methods comprise an analysis of genomic DNA in an individual for an allele of the 5- lipoxygenase promoter, which confers

an increased susceptibility to atherosclerosis. Individuals are screened by analyzing their genomic 5-LO gene sequence for the presence of a predisposing allele, as compared to a normal 5-LO sequence. The normal 5-LO sequence shall be understood to include sequence variants in non-coding regions that do not affect the level of expression of the gene, and coding region variants that do not change the amino acid sequence, e.g. "third position" changes.

The effect of a sequence variation on 5-LO expression or function can be determined by analysis for segregation of the sequence variation with the disease phenotype, e.g. incidence of CAD, presence of glucose tolerance, insulin levels, etc. A predisposing mutation will segregate with incidence of the disease. As an alternative to kindred studies, biochemical studies are performed to determine whether a candidate sequence variation in the 5-LO coding region or control regions affects the quantity or function of the protein. Expression levels of a candidate variant allele are compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β -galactosidase, chloramphenical acetyltransferase, etc. that provides for convenient quantitation; and the like.

A number of methods are used for determining the presence of a predisposing mutation in an individual. Genomic DNA is isolated from the individual or individuals that are to be tested. DNA can be isolated from any nucleated cellular source such as blood, hair shafts, saliva, mucous, biopsy, feces, etc. Methods using PCR amplification can be performed on the DNA from a single cell, although it is convenient to use at least about 10^5 cells. Where large amounts of DNA are available, the genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis, or amplified by conventional techniques. Of particular interest is the use of the polymerase chain reaction (PCR) to amplify the DNA that lies between two specific primers. The use of the polymerase chain reaction is described in Saiki *et al.* (1985) Science 239:487, and a review of current techniques may be found in McPherson *et al.* (2000) PCR (Basics: From Background to Bench) Springer Verlag; ISBN: 0387916008. A detectable label may be included in the amplification reaction. Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. ^{32}P , ^{35}S , ^3H ; etc. The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a

high affinity binding partner, *e.g.* avidin, specific antibodies, *etc.*, where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

5 Primer pairs are selected from the 5-LO genomic sequence using conventional criteria for selection. The primers in a pair will hybridize to opposite strands, and will collectively flank the region of interest. The primers will hybridize to the complementary sequence under stringent conditions, and will generally be at least about 16 nt in length, and may be 20, 25 or 30 nucleotides in length. The primers will be selected to amplify the
10 specific region of the 5-LO gene suspected of containing the predisposing mutation. Typically the length of the amplified fragment will be selected so as to allow discrimination between repeats of 3 to 7 units. Multiplex amplification may be performed in which several sets of primers are combined in the same reaction tube, in order to analyze multiple exons simultaneously. Each primer may be conjugated to a different label.

15 A diagnostic screening method of particular interest detects the number of SP-1 repeats in the promoter region of the human 5-LO gene. The organization of the region comprises a repeat region of from about 3 to about 7 6 base pair repeats of the binding motif GGGCGG, flanked by unique sequences. Within the 5' and 3' flanking sequences, sequences are selected for amplification primers. The exact composition of the primer
20 sequences are not critical to the invention, but they must hybridize to the flanking sequences under stringent conditions. Criteria for selection of amplification primers are as previously discussed. To maximize the resolution of size differences at the locus, it is preferable to chose a primer sequence that is close to the repeat sequence, such that the total amplification product is at least about 30, more usually at least about 50, preferably at
25 least about 100 or 200 nucleotides in length, which will vary with the number of repeats that are present, to not more than about 500 nucleotides in length. The number of repeats has been found to be polymorphic, as previously described, thereby generating individual differences in the length of DNA that lies between the amplification primers.

 The primers are used to amplify the region of genomic DNA that contains the
30 repeats. Conveniently, a detectable label will be included in the amplification reaction, as previously described. Multiplex amplification may be performed in which several sets of primers are combined in the same reaction tube. This is particularly advantageous when limited amounts of sample DNA are available for analysis. Conveniently, each of the sets of primers is labeled with a different fluorochrome.

35 After amplification, the products are size fractionated. Fractionation may be performed by gel electrophoresis, particularly denaturing acrylamide or agarose gels. A convenient system uses denaturing polyacrylamide gels in combination with an automated

DNA sequencer, see Hunkapillar et al. (1991) Science 254:59-74. The automated sequencer is particularly useful with multiplex amplification or pooled products of separate PCR reactions. Capillary electrophoresis may also be used for fractionation. A review of capillary electrophoresis may be found in Landers, et al. (1993) BioTechniques 14:98-111.

- 5 The size of the amplification product is proportional to the number of repeats (n) that are present at the locus specified by the primers. The size will be polymorphic in the population, and is therefore an allelic marker for that locus.

The amplified or cloned fragment may be sequenced by dideoxy or other methods, and the length of the amplified region, or the sequence of bases, is compared to the normal
10 5-LO sequence. Alternatively, where the predisposing mutation creates or destroys a recognition site for a restriction endonuclease, the fragment is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel electrophoresis, particularly acrylamide or agarose gels. Hybridization with the variant sequence may also be used to determine its
15 presence, by Southern blots, dot blots, etc. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices is used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilised on a
20 microarray, may also be used as a means of detecting the presence of variant sequences.

The presence of a predisposing mutation is indicative that an individual is at increased risk of developing atherosclerosis and/or hyperglycemic disease. The diagnosis of a disease predisposition allows the affected individual to seek early treatment of potential lesions, and to avoid activities that increase risk for cardiovascular disease.

25 In addition to atherosclerosis and other cardiovascular disease, 5-LO polymorphisms are associated with insulin resistance. Insulin resistance occurs in 25% of non-diabetic, non-obese, apparently healthy individuals, and predisposes them to both diabetes and coronary artery disease. Hyperglycemia in type II diabetes is the result of both resistance to insulin in muscle and other key insulin target tissues, and decreased beta
30 cell insulin secretion. Longitudinal studies of individuals with a strong family history of diabetes indicate that the insulin resistance precedes the secretory abnormalities. Prior to developing diabetes these individuals compensate for their insulin resistance by secreting extra insulin. Diabetes results when the compensatory hyperinsulinemia fails. The secretory deficiency of pancreatic beta cells then plays a major role in the severity of the
35 diabetes.

However, even without developing hyperglycemia and diabetes, these insulin resistant individuals pay a significant price in terms of general health. Insulin resistance

results in an increased risk for having elevated plasma triglycerides (TG), lower high density lipoproteins (HDL), and high blood pressure, a cluster of abnormalities that have been termed by different investigators as either Syndrome X, the insulin resistance syndrome, or the metabolic syndrome. It is believed that either the hyperinsulinemia, insulin resistance, or both play a direct role in causing these abnormalities. Data from ethnic, family, and longitudinal studies suggest that a major component of resistance is inherited.

The most practical way of assessing insulin resistance is the homeostasis model assessment (HOMAIR), involving fasting insulin and glucose levels. This value is calculated as fasting plasma insulin ($\mu\text{U}/\text{ml}$) \times fasting plasma glucose (mmol/L)/22.5 (Matthews et al. (1985) *Diabetologia*. 28:412-9). The steady-state basal plasma glucose and insulin concentrations are determined by their interaction in a feedback loop. A computer-solved model is been used to predict the homeostatic concentrations that arise from varying degrees beta-cell deficiency and insulin resistance. Comparison of a patient's fasting values with the model's predictions allows a quantitative assessment of the contributions of insulin resistance and deficient beta-cell function to the fasting hyperglycaemia. The estimate of insulin resistance obtained by homeostasis model assessment correlates with estimates obtained by use of the euglycaemic clamp, the fasting insulin concentration, and the hyperglycaemic clamp. The lower limit of the top quintile of HOMA(IR) distribution (i.e. 2.77) in nonobese subjects with no metabolic disorders has been chosen as the threshold for insulin resistance in some studies (Bonora et al. (1998) *Diabetes* 47:1643-9). The results of this study documented that 1) in hypertriglyceridemia and a low HDL cholesterol state, insulin resistance is as common as in NIDDM, whereas it is less frequent in hypercholesterolemia, hyperuricemia, and hypertension; 2) the vast majority of subjects with multiple metabolic disorders are insulin resistant; 3) in isolated hypercholesterolemia, hyperuricemia, or hypertension, insulin resistance is not more frequent than can be expected by chance alone; and 4) in the general population, insulin resistance can be found even in the absence of any major metabolic disorders.

The measurement of insulin concentration can be done in the overnight fasted condition, since in the postprandial state, glucose levels are changing rapidly and the variable levels of glucose confound the simultaneous measure of insulin levels as an index of insulin action. There is a significant correlation between fasting insulin levels and insulin action as measured by the clamp technique. Very high plasma insulin values in the setting of normal glucose levels are very likely to reflect insulin resistance. As individuals develop diabetes, plasma glucose increases and plasma insulin decreases and so the plasma insulin level no longer reflects only insulin resistance because it becomes influenced by the appearance of a β -cell defect and hyperglycemia.

The 5-LO genes have been found to be differentially expressed in an animal model for atherosclerosis. "Differential expression" as used herein refers to both quantitative as well as qualitative differences in the genes' temporal and/or tissue expression patterns. Thus, a differentially expressed gene may have its expression diminished or inactivated in protective versus susceptible cardiovascular conditions. The 5-LO gene therefore finds use in screening for agents that modulate expression or activity, and which find use in treatment of cardiovascular disease. Drug candidates of interest include known 5-LO inhibitors, many of which are known in the art, for example zileuton, ABT-761 (see Drazen *et al.*, *supra.*); 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines as disclosed in U.S. Patent no. 6,294,574; compounds described in U.S. Patent no. 6,194,585, and the like.

Screening assays identify compounds that modulate the expression or activity of 5-LO. A 5-LO inhibitor can, for example, act as the basis for amelioration of such cardiovascular diseases as atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Such compounds may include, but are not limited to peptides, antibodies, or small organic or inorganic compounds. Methods for the identification of such compounds are described below.

Cell- and animal-based systems can act as models for cardiovascular disease and are useful in such drug screening. The animal- and cell-based models may be used to identify drugs, pharmaceuticals, therapies and interventions that are effective in treating cardiovascular disease. In addition, such animal models may be used to determine the LD₅₀ and the ED₅₀ in animal subjects, and such data can be used to determine the *in vivo* efficacy of potential cardiovascular disease treatments. Animal-based model systems of cardiovascular disease may include, but are not limited to, non-recombinant and engineered transgenic animals. Non-recombinant, non-genetic animal models of atherosclerosis may include, for example, pig, rabbit, or rat models in which the animal has been exposed to either chemical wounding through dietary supplementation of LDL, or mechanical wounding through balloon catheter angioplasty, for example. Additionally, animal models exhibiting cardiovascular disease symptoms may be engineered by utilizing, for example, 5-LO gene sequences in conjunction with techniques for producing transgenic animals that are well known to those of skill in the art. For example, target gene sequences may be introduced into, and knocked out or overexpressed in the genome of the animal of interest. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate cardiovascular disease animal models.

Any technique known in the art may be used to introduce a target gene transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P. C. and Wagner, T. E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson et al., 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57:717-723); etc.

Specific cell types within the animals may be analyzed and assayed for cellular phenotypes characteristic of cardiovascular disease. In the case of monocytes, such phenotypes may include but are not limited to increases in rates of LDL uptake, adhesion to endothelial cells, transmigration, foam cell formation, fatty streak formation, and production of foam cell specific products. Further, such cellular phenotypes may include a particular cell type's fingerprint pattern of expression as compared to known fingerprint expression profiles of the particular cell type in animals exhibiting cardiovascular disease symptoms.

Cells that contain and express 5-LO can be utilized to identify compounds that exhibit anti-cardiovascular and/or anti-hyperglycemic disease activity. In the case of monocytes, such phenotypes may include but are not limited to increases in rates of LDL uptake, adhesion to endothelial cells, transmigration, foam cell formation, fatty streak formation, and production by foam cells of growth factors such as bFGF, IGF-I, VEGF, IL-1, M-CSF, TGF β , TGF α , TNF α , HB-EGF, PDGF, IFN- γ and GM-CSF. Transmigration rates, for example, may be measured using an *in vitro* system to quantify the number of monocytes that migrate across the endothelial monolayer and into the collagen layer of the subendothelial space.

Cells of a cell type known to be involved in cardiovascular and/or hyperglycemic disease may be transfected with sequences capable of increasing or decreasing the amount of 5-LO gene expression within the cell. For example, 5-LO gene sequences may be introduced into, and overexpressed in, the genome of the cell of interest, or, if endogenous target gene sequences are present, they may be either overexpressed or, alternatively disrupted in order to underexpress or inactivate target gene expression.

Transfection of target gene sequence nucleic acid may be accomplished by utilizing standard techniques. Transfected cells can be evaluated for the presence of the recombinant 5-LO gene sequences, for expression and accumulation of 5-LO gene mRNA, and for the presence of recombinant 5-LO protein. Where a decrease in 5-LO gene expression is desired, standard techniques may be used to demonstrate whether a decrease in expression is achieved.

In vitro systems may be designed to identify compounds capable of inhibiting 5-LO. Such compounds may include, but are not limited to, peptides made of D-and/or L-configuration amino acids, phosphopeptides, antibodies, and small organic or inorganic molecules. The principle of the assays used to identify compounds that inhibit 5-LO involves preparing a reaction mixture of 5-LO and a test compound under conditions and for a time sufficient to allow the two components to interact, and detecting the resulting change in the catalytic activity in the formation of leukotrienes. Alternatively, a simple binding assay can be used as an initial screening method. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring 5-LO protein or a test substance onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In another embodiment of such a method, the assay tests the presence of products catalyzed by 5-LO.

For example, a routine assay of 5-LO activity can be performed in a mixture containing 50 mM potassium phosphate buffer at pH 7.4, 2 mM CaCl_2 , 2 mM ATP, 25 M arachidonic acid (0.1 Ci) and 5-LO enzyme (50-100 mg of protein) in a final volume of 200 ml. The reaction is carried out at 24° C. for 3 minutes. The mixture is extracted with 0.2 ml of an ice-cold mixture of ethyl ether:methanol: 0.2 M citric acid (30:4:1). The extract is subjected to thin-layer chromatography at -10° C. in a solvent system of petroleum ether:ethyl ether:acetic acid (15:85:0.1). The silica gel zones corresponding to authentic arachidonic acid and its metabolites are scraped into scintillation vials for counting. The enzyme activity is expressed in terms of the amount of arachidonic acid oxygenated for 3 minutes.

In a binding assay, the reaction can be performed on a solid phase or in liquid phase. In a solid phase assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a binding reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for target gene product or the test compound to anchor any

complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

Cell-based systems such as those described above may be used to identify compounds that act to ameliorate cardiovascular disease symptoms. For example, such cell systems may be exposed to a test compound at a sufficient concentration and for a time sufficient to elicit such an amelioration of cardiovascular disease symptoms in the exposed cells. After exposure, the cells are examined to determine whether one or more of the cardiovascular disease cellular phenotypes has been altered to resemble a more normal or more wild type, non-cardiovascular disease phenotype. For example, and not by way of limitation, in the case of monocytes, such more normal phenotypes may include but are not limited to decreased rates of LDL uptake, adhesion to endothelial cells, transmigration, foam cell formation, fatty streak formation, and production by foam cells of growth factors such as bFGF, IGF-I, VEGF, IL-1, M-CSF, TGF β , TGF α , TNF α , HB-EGF, PDGF, IFN- γ and GM-CSF.

In addition, animal-based disease systems, such as those described, above may be used to identify compounds capable of ameliorating disease symptoms. Such animal models may be used as test substrates for the identification of drugs, pharmaceuticals, therapies, and interventions, which may be effective in treating disease. For example, animal models may be exposed to a compound, suspected of exhibiting an ability to ameliorate cardiovascular disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of disease symptoms in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with disease, for example, by counting the number of atherosclerotic plaques and/or measuring their size before and after treatment.

With regard to intervention, any treatments that reverse any aspect of cardiovascular disease symptoms or insulin resistance and other hyperglycemic conditions should be considered as candidates for human disease therapeutic intervention. Dosages of test agents may be determined by deriving dose-response curves.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀ /ED₅₀. Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound. For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g.,

dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific 5-LO nucleic acid reagent described herein, which may be conveniently used, e.g., in clinical settings, for prognosis of patients susceptible to cardiovascular disease.

Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In this specification and the appended claims, the singular forms "a," "an" and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

5 Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also
10 encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this
15 invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the subject components of the invention that are
20 described in the publications, which components might be used in connection with the presently described invention.

EXPERIMENTAL

Atherosclerosis is initiated by the trapping and oxidation of low-density lipoproteins
25 (LDL) in the subendothelial layer of the artery wall, resulting in the formation of biologically active species that stimulate vascular cells to produce inflammatory molecules. This signals a cascade of leukocyte recruitment, further lipoprotein oxidation, foam cell formation, necrosis, and fibroproliferation. To identify genes that contribute to this complex process, we previously constructed a cross between an atherosclerosis-resistant mouse strain,
30 CAST, and a susceptible strain, B6. A major locus for atherosclerosis was identified on mouse chromosome 6 and was subsequently confirmed with the congenic strain designated CON6 in which the central region of chromosome 6 from CAST was bred onto a B6 background. These CON6 mice had reduced insulin levels and dramatically decreased lesion formation when bred onto an LDL receptor-null (LDLR^{-/-}) background and fed an
35 atherogenic diet. Moreover, bone marrow transplantation studies indicated that the resistant phenotype was conferred in part by bone marrow-derived cells.

In examining the congenic region for potential positional candidate genes, we observed that 5-lipoxygenase (5-LO) mapped directly underneath the linkage peak for the locus. 5-LO is the rate-limiting enzyme in leukotriene (LT) biosynthesis and is expressed primarily in leukocytes, including monocytes and macrophages. Leukotrienes are potent
5 proinflammatory lipid mediators derived from arachidonic acid and have been shown to affect several pathophysiological conditions. Therefore, 5-LO could potentially contribute to the development of atherosclerosis through lipid oxidation and/or inflammatory processes. The contribution of 5-LO to atherosclerotic lesion formation was examined, based on its location within the chromosome 6 congenic region, its role in inflammation, and its
10 expression in leukocytes. The results indicate that 5-LO participates in atherogenesis.

Materials and Methods

Animal Husbandry. Mice were purchased from the Jackson Laboratories, Bar Harbor, Maine, and housed 4 per cage at 25°C on a 12-hour light/dark cycle. They were
15 maintained either on a chow diet or a high-fat, high-cholesterol diet containing 15% fat, 1.25% cholesterol, and 0.5% cholic acid (diet No. 90221, Harlan-Teklad). The mice used in the experiments described below were of both sexes and between 4 to 6 months of age. All procedures were in accordance with current National Institutes of Health guidelines and were approved by the UCLA Animal Research Committee.

20 5-LO^{-/-} mice on a B6 background were generated as described previously. To generate double knockout animals, 5-LO^{-/-} mice were first bred to LDLR^{-/-} mice (also on a B6 background), and the F1 progeny were backcrossed to LDLR^{-/-} mice to produce 5-LO^{+/-} / LDLR^{-/-} mice. These mice were then intercrossed to generate double knockout animals. Although a small number of 5-LO^{-/-} / LDLR^{-/-} mice were obtained, they did not produce
25 offspring. Therefore, the experiments described herein were performed with 5-LO^{+/-} / LDLR^{-/-} mice. The segregation of the 5-LO^{-/-} mutation was followed using PCR primers specific for the targeted allele (neo primer) (SEQ ID NO:2) 5'-ATCGCCTTCTTGACGAGTTC-3'; downstream primer for both +/+ and KO within intron 6 (SEQ ID NO:3) 5'-GCAGGAAGTGGCTACTGTGGA-3'; primer specific to +/+ 5'-(SEQ ID NO:4)
30 TGCAACCCAGTACTCATCAAG-3'. PCR primers used for the LDLR +/+ allele were (SEQ ID NO:5) 5'-ACCCCAAGACGTGCTCCCAGGATGA-3' and (SEQ ID NO:6) 5'-CGCAGTGCTCCTCATCTGACTTGT-3' and for the mutant allele were (SEQ ID NO:7) 5'-AGGATCTCGTCGTGACCCATGGCGA-3' and (SEQ ID NO:8) 5'-GAGCGGCGATACCGTAAAGCACGAGG-3'.

35 *Plasma Lipid and Insulin Measurements.* Mice were fasted overnight and bled retro-orbitally under isoflurane anesthesia. Enzymatic assays for plasma cholesterol levels were

performed as described previously. Insulin levels were measured in duplicate by ELISA (Crystal Chemical IUSKRO20).

Northern Blot Analysis Total RNA was isolated from bone marrow cells using Trizol reagent (Life Technologies Inc). The RNA (10 µg) was run on a 1% agarose formaldehyde gel, transferred to nylon membrane, and hybridized with a 700-bp mouse-specific probe from the 3' end of the 5-LO cDNA. The blots were stripped and probed for GAPDH as an internal control. Levels of 5-LO mRNA were quantitated by phosphorimaging and are expressed as the ratio of 5-LO to GAPDH mRNA.

Western Blot Analysis. Homogenates of bone marrow cells (80 µg protein) in SDS sample buffer were subjected to electrophoresis on NuPAGE 4% to 12% precast SDS polyacrylamide gradient gels (Novex) under reducing conditions as suggested by the manufacturer. Proteins were transferred to nitrocellulose membranes, incubated (1:3000 dilution) overnight with antibodies to 5-LO, LTA₄ hydrolase, or LTB₄ omega-hydroxylase (Cayman Chemical), and visualized by ECL detection (Amersham, Little Chalfont). Image-Quant software (Molecular Dynamics) was used for the quantification of bands, which were normalized to GAPDH.

Measurement of LTB₄ Levels. LTB₄ levels were determined in duplicate using a commercially available ELISA kit (Cayman Chemical). Assays were performed on bone marrow cells (25 µg protein) homogenized in 10 mmol/L Tris, pH 8.0.

Sequence Analysis of 5-LO cDNA. cDNA was prepared from peritoneal macrophage RNA of CAST and B6 mice using an Superscript rtPCR kit (Gibco BRL). The PCR primers used for sequencing were as follows: (SEQ ID NO:9) 5'-ATGCCCTATGCCCTCCTACACTGTCAC-3' (SEQ ID NO:10) 5'-CCACTCCATCCATCTATACTG-3'; (SEQ ID NO:11) 5'-GCAGCACAGACGTAAAGAACTG-3'; (SEQ ID NO:12) 5'-GAGGAAGTCACTGGAACGCAC; (SEQ ID NO:13) 5'-CTACGGATTCAAAGTACGACTG-3' (SEQ ID NO:14) CAGGTACTCGGACAGCTTCTC-3'; (SEQ ID NO:15) 5'-GCTATCCAGTCGTTACGATG-3' (SEQ ID NO:16) 5'-GCAGCACTTCGAGCTTGGAAG-3'. The products were purified and sequenced by Laragen, Inc. (Los Angeles). The results were analyzed by the use of programs available through NCBI.

Isolation of Bone Marrow Cells and Peritoneal Macrophages. Bone marrow cells were flushed from mouse femurs with DMEM/5% fetal calf serum (FCS) and centrifuged at 1500 RPM for 15 minutes (3 repetitions of washing and centrifugation). Peritoneal macrophages were isolated after lavage with DMEM/5% FCS, as described for bone marrow cells.

Measurement of 5-LO by Immunohistochemistry. Immunostaining was performed on aortic lesion cryostat sections from apolipoprotein E^{-/-} (apoE^{-/-}) and LDLR^{-/-} mice, as

described below. Alternate sections were fixed with formaldehyde, washed with PBS, and incubated in blocking buffer, followed by either rabbit anti-human 5-LO (Cayman Chemical, Mich) or rat anti-mouse MOMA-2 (Accurate Chemical, NY) antiserum. The sections were then washed and incubated with biotinylated goat anti-rabbit IgG at a dilution of 1:200. After
5 extensive washing, the macrophages and 5-LO protein were visualized by alkaline phosphatase using Vector Red as substrate. Appropriate control experiments, including omission of primary antibody, were performed. Peritoneal monocyte/macrophages were harvested with 20 mL DMEM/5% FCS 3 days after 4% thioglycolate (DIFCO, MI) injection. The cells were centrifuged at 1500 rpm, washed 3 times with media, and cultured overnight
10 on glass slides. The slides were stained with a 1:200 dilution of rabbit anti-human 5-LO and hematoxylin.

Aortic Lesion Analysis After 8 weeks on a high-fat, high-cholesterol diet, mice were euthanized and the upper portion of the heart and proximal aorta were removed, embedded in OCT compound (Miles Laboratories), and stored at -70°C. Serial 10 µm-thick
15 cryosections from the middle portion of the left ventricle of the aortic arch were collected and mounted on poly-D-lysine-coated plates. Sections were stained with oil red O and hematoxylin, and the lipid staining areas were counted in a blinded fashion by light microscopy.

Bone Marrow Transplantation . Four-month-old LDLR ^{-/-} mice were used as
20 recipients for bone marrow transplanted from either 3-month-old 5-LO ^{+/-} /LDLR ^{-/-} mice or control LDLR ^{-/-} mice. Recipient mice were lethally irradiated and then injected with 10⁷ bone marrow cells through the tail vein, as described previously. Four weeks after transplantation, DNA from blood-derived leukocytes was analyzed for the presence of the targeted 5-LO allele, and the animals were placed on the high-fat, high-cholesterol diet for 8
25 weeks.

Statistical Analyses. Differences in measured variables between groups of mice were determined by ANOVA (Statview version 5.0). Values are expressed as mean±SEM, and differences were considered statistically significant at P±0.05.

30 Results

CON6 Mice Have Reduced Expression of 5-LO. Quantitative trait locus mapping of a cross between resistant CAST and susceptible B6 mice for atherosclerotic lesion development revealed a locus with a powerful effect on atherosclerosis on mouse chromosome 6. Subsequently, a congenic strain, CON6, containing the locus derived from
35 CAST on the background of B6 was constructed. The congenic strain was almost entirely resistant to atherosclerosis, even when an LDL receptor-null mutation was introduced. These studies defined the critical region of the gene to between ~45 cM and 74 cM on

mouse chromosome 6. To complement this approach, various candidate genes within the locus were tested. The 5-LO gene is located near the middle of the congenic region, at ~53 cM.

Given the proinflammatory properties of 5-LO and leukotrienes, it was reasoned that variation in the 5-LO gene could be involved in the resistance to atherosclerosis of the CON6 mice. To examine this possibility, the expression of mRNA for 5-LO was quantitated in bone marrow cells, a tissue previously shown to synthesize 5-LO. Northern blot analysis was performed using a mouse 5-LO cDNA probe and the signal was quantitated using a PhosphorImager and GAPDH as an internal control.

As shown in Figure 1A, CON6 mice on an LDL receptor-null background exhibited only about 15% of the mRNA levels of LDLR^{-/-} mice. Similarly, CON6 mice exhibited a very significant reduction in 5-LO protein levels compared with B6 controls, as determined by immunoblot analysis (Figure 1B). Densitometric analysis of the blots indicated that CON6 mice have approximately 25% of the levels of 5-LO protein as B6 mice. 5-LO catalyzes the oxidation of arachidonic acid to 5-HPETE and LTA₄, which is then converted to LTB₄ by LTA₄ hydrolase. As measured by ELISA assay, LTB₄ levels in CON6 mice were only a few percent of those in B6 mice (Figure 2A), demonstrating that 5-LO activity is also reduced in CON6 mice. LTA₄ hydrolase and LTB₄ ω -hydroxylase are 2 downstream enzymes from 5-LO and were also examined in bone marrow cells by immunoblot analysis (Figure 2B). The protein levels of LTA₄ hydrolase and LTB₄ ω -hydroxylase were both increased in CON6 versus B6 mice, suggesting that these enzymes are upregulated in response to decreased 5-LO levels.

Sequence Variation Between B6 and CAST 5-LO cDNA. The 5'UTR and coding region of 5-LO cDNA were sequences from B6 and CAST mice to examine possible variations that could influence the enzyme's synthesis and/or function (provided herein as SEQ ID NO:17 and SEQ ID NO:18). The 5-LO sequence is highly conserved between the 2 strains with only 6 nucleotide changes, 4 of which did not result in amino acid substitution. The 2 amino acid changes occurred at residue 645, where B6 has an isoleucine and CAST has a valine, and at 646, where B6 has a valine and CAST has an isoleucine.

5-LO Is Expressed in Atherosclerotic Lesions and in Macrophages. To determine whether 5-LO is present in atherosclerotic lesions, immunohistochemical studies of mouse aortic sections were performed. The proximal aortas (from the aortic root up to the aortic arch) of apoE^{-/-} and LDLR^{-/-} mice were sectioned and stained with antibody to either 5-LO or the macrophage-specific marker, MOMA-2 (Figure 3). As expected, staining with oil red O revealed the presence of large lipid-filled areas and a necrotic core within the lesions of

both apoE^{-/-} and LDLR^{-/-} mice. Staining with MOMA-2, a macrophage-specific marker also revealed sites of infiltration of monocyte/macrophages into the subendothelial space (3A-C). The adjacent sections, stained with 5-LO antibody, revealed abundant 5-LO protein staining that appeared to colocalize, at least in part, with a subset of monocyte/macrophages (Figures 3D through 3F). Interestingly, 5-LO staining was not present in all regions containing monocyte/macrophages, as evident from the LDLR^{-/-} sections (3C and F). We next tested whether the expression of 5-LO in macrophages from CON6 and B6 mice by immunostaining the cells with antiserum against 5-LO. As shown in Figure 4, B6 macrophages exhibited significant 5-LO staining, whereas CON6 macrophages had dramatically reduced staining.

Deficiency of 5-LO Dramatically Reduces Atherosclerosis in an LDLR^{-/-} Model.

Given the dramatically reduced size of aortic lesions and reduced expression of 5-LO in CON6 mice, shown in Table 1, we assessed the involvement of 5-LO in lesion development by examining atherosclerosis in 5-LO knockout mice, previously constructed by Funk and colleagues.

5-LO-null mice were bred on a B6 background, with LDL receptor-null mice, also on a B6 background. The frequency of double knockout mice was much lower than expected based on Mendelian segregation, presumably because the two mutations are incompatible with life. Because the CON6 mice exhibited reduced, but not absent, 5-LO activity, we examined mice heterozygous for the 5-LO-null mutation on an LDL receptor-null background. 5-LO protein levels did not differ in LDL^{-/-} mice fed either a chow or high-fat, high-cholesterol diet (Figure 5). However, there were decreased levels of 5-LO mRNA (Figure 1A) and protein (Figure 5) in the 5-LO^{+/-}/LDL^{-/-} mice compared with LDLR^{-/-} mice on a chow diet, which was less than the 50% that would be expected from heterozygotes. Because homozygous double knockout mice were not obtained either, it is possible that there is an interaction between LDLR and 5-LO such that disruption of both leads to altered expression of one or both genes as well as incompatibility with life.

After feeding of an atherogenic diet for 8 weeks, a striking effect of 5-LO on atherosclerosis was observed. As expected, the 5-LO^{+/-}/LDLR^{-/-} control mice had large advanced lesions, with an average area of 153,080±21,010 μm². The 5-LO^{+/-}/LDLR^{-/-} mice, on the other hand, had an aortic lesion area of only 5830±2080 μm² (Figure 6A). Thus, mice heterozygous for the 5-LO-null mutation had over a 26-fold decrease (P<0.0005) in lesion size despite having cholesterol levels similar to LDLR^{-/-} mice, exceeding 500 mg/dL (Figure 6B). This reduction in atherosclerosis was very similar to what we previously observed when the CON6 locus was transferred onto the LDLR^{-/-} background 3 and indicates that 5-LO has a dose-dependent effect on lesion size.

5-LO^{+/-} Mice on an LDLR^{-/-} Background Have Reduced Insulin Levels. In previous studies of the CAST B6 intercross, we observed a significant quantitative trait locus for insulin levels on chromosome 6 that was coincident with the locus for lesion formation.

Moreover, the CON6 strain exhibited decreased insulin levels as compared with B6 mice. To examine whether 5-LO could also account, in part, for the linkage of insulin to this locus, we measured insulin levels in the 5-LO^{+/-} /LDLR^{-/-} mice. Analogous to the lesion results, heterozygosity for a 5-LO-null allele on an LDL^{-/-} background decreased insulin levels 3-fold compared with 5-LO^{+/+} /LDLR^{-/-} controls (Figure 7). This suggests that variations of the 5-LO gene may also have a role in regulation of insulin levels associated with this locus.

Bone Marrow Transplantation of the 5-LO^{+/-} Allele Confers Resistance to Atherosclerosis. We previously demonstrated that transplantation of CON6 bone marrow into B6 mice resulted in an approximate 2-fold decrease in lesion formation, consistent with the concept that the genetic variation between CON6 and B6 strains is due, in part, to leukocyte functions. To test whether 5-LO^{+/-} mice exhibited a similar bone marrow-dependent effect on atherosclerosis, we transplanted either 5-LO^{+/-} /LDLR^{-/-} or 5-LO^{+/+} /LDLR^{-/-} bone marrow into LDL receptor-deficient mice. Successful transplantation was confirmed 4 weeks after the procedure, as previously described. After 8 weeks on a high-fat, high-cholesterol diet, 5-LO mRNA remained significantly decreased in peritoneal macrophages from LDLR^{-/-} mice trans-planted with 5-LO^{+/-} /LDLR^{-/-} marrow, indicative of successful bone marrow transplantation.

Consistent with the CON6 findings, LDLR^{-/-} mice receiving 5-LO^{+/-} bone marrow exhibited a 2-fold decrease in atherosclerosis compared with controls (Figures 8A and 8B), suggesting that the 5-LO in macrophages is involved in lesion formation. Presumably, artery wall cells other than those derived from bone marrow are also involved in atherosclerosis, which may explain why transplantation of 5-LO- deficient bone marrow does not decrease lesions to the same extent as global disruption of 5-LO^{+/-}.

The present study provides compelling evidence that the positional candidate gene, 5-LO, is involved in the development of atherosclerotic lesions. Most significantly, heterozygous deficiency for the enzyme in a knockout model decreased lesion size in LDLR^{-/-} mice by about 95%, an effect far greater than any other gene, with the possible exception of macrophage colony stimulating factor (MCSF). The enzyme was expressed abundantly in macrophage-rich regions of atherosclerotic lesions, suggesting that 5-LO and/or its products may act locally to promote lesion development. There are a number of potential mechanisms by which these products may act. These include the following: seeding of LDL

by oxidation products produced by the 5-LO pathway; the production of natural ligands for nuclear receptors, such as peroxisome proliferator-activated receptor α (PPAR α); and various autocrine and paracrine effects mediated through G protein-associated primary receptors for leukotrienes. Such effects could potentially influence specific immunity
5 functions, such as the differentiation and migration of other cells.

It is interesting to note that transplantation of 5-LO-deficient bone marrow did not decrease atherosclerosis to the same extent as that observed in the 5-LO ^{+/-} mice. One explanation is that the host myeloid cells may not all be totally abolished, even with irradiation of the recipient before transplantation. Subsequent blood cells in the recipient
10 would thus not be derived entirely from the donor. In addition, certain lymphocytes and the Kupffer cells of the liver, which have long half-lives, would not be replaced as a result of transplantation and still remain from the recipient. Lastly, 5-LO is expressed in endothelial cells, albeit at very low levels, which could continue to promote lesion development and the inflammatory state of the artery wall even in the absence of macrophage 5-LO. In contrast,
15 global disruption of 5-LO would presumably decrease its expression in endothelial cells to an even greater extent than that in macrophages and thus account for the greater reduction of atherosclerosis observed in the 5-LO knockout mice.

Our studies also provide strong presumptive evidence that variations of the 5-LO gene explain the resistance to atherosclerosis observed in CON6 mice. This possibility is
20 supported by the following lines of evidence: (1) 5-LO is a reasonable candidate based on its known proinflammatory properties; (2) 5-LO is expressed in macrophage-rich regions of mouse lesions; (3) 5-LO is decreased similarly in CON6 mice and heterozygous 5-LO knockout mice, and both have a similar, dramatic effect on atherosclerosis; (4) insulin levels are decreased in both CON6 and heterozygous 5-LO knockout mice; and (5) bone marrow
25 transplantation of CON6 or heterozygous 5-LO knockout bone marrow had a similar (~2- to 3-fold decrease) effect on atherosclerosis in LDLR ^{-/-} mice.

Although the most straightforward explanation for the effect of 5-LO on atherosclerosis in CON6 mice is the decreased expression, it is possible that structural differences also contribute. Sequencing of B6 and CAST 5-LO cDNA revealed two amino
30 acid differences between the two strains at positions 645 (CAST/Val; B6/Ile) and 646 (CAST/Ile; B6/Val). 5-LO is highly conserved among mammals and the human and rat sequences are identical with that of B6 at positions 645 and 646. It is not known whether these substitutions influence 5-LO function but they may influence the cellular trafficking of 5-LO. For example, these two residues are within a conserved region of basic amino acids,
35 from positions 639 to 656, found in many proteins that translocate from the cytosol to the nucleus. A synthetic 639 to 656 fusion peptide showed that this potential nuclear localization sequence (NLS) in 5-LO acts as a regulatory domain involved in the nuclear

translocation of the enzyme from the cytosol. In contrast, using a synthetic fusion peptide containing the last 90 amino acids of the 5-LO C-terminus, this peptide was not able to translocate into the nucleus. Due to the high conservation of this sequence in proteins containing a NLS, these amino acid substitutions could be potentially important in regulating the translocation of 5-LO to the nucleus.

The process by which atherosclerosis develops in the artery wall is complex and involves a variety of steps, such as lipid oxidation and leukocyte migration/proliferation. Studies in mice suggest that 12/15-LO is an important mediator of atherosclerosis, presumably due to "seeding" LDL with reactive oxygen species, leading to the production of proinflammatory LDL. The eicosanoid products of 5-LO could similarly promote lipoprotein oxidation, thereby contributing to inflammation and foam cell formation. 5-LO and its products have also been implicated in the chemotaxis of leukocytes, which may provide another mechanism for its proinflammatory role in atherosclerosis. For example, 5-HETE exhibits chemotactic activity, although only at relatively high concentrations. In neutrophils, dendritic cells, and monocyte/macrophages, 5-HETE can be converted to 5-oxo-EETE, which is ~10-fold more potent than 5-HETE in stimulating monocyte migration. Moreover, both 5-oxo-EETE and 5-HETE have been shown to synergistically induce monocyte migration in response to monocyte chemotactic protein-1 (MCP-1). These results become more relevant because LTB₄ and MCP-1 levels have been shown to cross-regulate each other. Studies have shown that intraperitoneal injection of MCP-1 induces production of LTB₄, whereas MCP-1 stimulates the production of LTB₄ from mouse peritoneal macrophage in a dose-dependent manner. These studies suggest that 5-LO and its product LTB₄ could promote atherosclerosis by recruiting monocytes to the vessel wall.

Several mechanisms have been proposed for LTB₄ activation of inflammatory responses, including the binding and activation of PPAR α and direct G protein signaling pathways mediated by the leukotriene receptors. PPAR α is expressed in all vascular cells and could play a role in vascular inflammation. For example, PPAR α mediates MCP-1 synthesis in mouse aortic endothelial cells when stimulated with minimally modified LDL or oxidized phospholipids. LTB₄ is one of the ligands that activates PPAR α and binds with an affinity in the nanomolar range. In addition, each leukotriene has a specific high-affinity G protein-coupled cell surface receptor, which can influence differentiation, migration, and immune functions. For example, LTB₄ receptor-null mutants had significant defects in neutrophil and macrophage recruitment and exhibited altered cellular function, such as changes in calcium flux. Thus, 5-LO and its metabolites may play an important role in atherosclerosis either as natural nuclear receptor ligands or through receptor-mediated inflammatory signaling pathways.

EXAMPLE 2

In a study of randomly ascertained individuals, we have observed evidence for an association between 5-LO polymorphisms and carotid artery intima-media thickness, a validated surrogate marker for atherosclerosis. Thus, genetic variation in 5-LO may also affect human heart disease. The results of this study provide further evidence for the important role that inflammatory mediators could play in atherosclerosis and may provide an avenue for implementing novel therapeutic strategies, because effective inhibitors of 5-LO have already been developed.

Based on the above mouse studies, the contribution of the 5LO gene to human atherosclerosis was assessed. These results demonstrate that 5LO is also involved in susceptibility to coronary artery disease (CAD) and diabetes in humans. For example, we observed that certain forms of the 5LO gene (termed deleted alleles) are found in CAD patients three times as often as they are in control subjects (9% vs. 3%; $P < .04$; Table 2). The nomenclature for the 5-LO genotype is as discussed in Drazen et al. (1999), supra. The genotype is determined by the number of Sp1 repeats in the promoter region, where 3 and 4 repeats are referred to as a "D", or deleted allele. 5 repeats is the "N", or normal allele; and 6 repeats is an "A", or addition allele. The genotyping is performed essentially as set forth in Drazen et al. Even though the at-risk group is only ~9% of the population, this has very significant health care implications since CAD is so prevalent.

Table 2
CAD and 5-LO Genotype

	No CAD	Yes CAD	Total
DD	16	5*	21
DN	132	18	150
NN	350	32	382
Total	498	55	553

* P value is 0.04, $X^2 = 6.263$

The deleted alleles also lead to significantly higher fasting insulin levels (figure 9) as well as insulin resistance (HOMA analysis; figure 10), both of which are known risk factors for diabetes. Taken together, these results strongly suggest that genetic variation in the 5LO gene contributes to CAD-related traits in the human population, with deleted alleles predisposing individuals to CAD and diabetes. Given the importance and frequency of CAD in the US and other Western societies, we believe that identification of individuals who are carriers of deleted alleles would serve as a beneficial and powerful screening test in the general population or for those who are already at risk of developing CAD.

We have developed a method that can be used as a diagnostic DNA test to determine the form of the 5LO gene that an individual has. PCR is used to amplify a portion of the 5LO gene from an individual. Based on the size of this amplified fragment, it is possible to determine whether an individual carries the normal form (wildtype allele) or a variant version (deleted allele) of the 5LO gene. There are currently no genetic tests available for common forms of CAD or diabetes, which by far accounts for most of the heart attacks that individuals suffer. Given the importance and prevalence of CAD and diabetes, we believe that this is the first such test that can be widely used to identify at-risk individuals in the population.

It is evident that subject invention provides a convenient and effective way of determining whether a patient will be susceptible to atherosclerosis and hyperglycemic disease. The subject methods will provide a number of benefits, including preventive treatment and diet. As such, the subject invention represents a significant contribution to the art.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method for detecting a predisposition to atherosclerosis in an individual, the method comprising:

analyzing an individual for quantitative or qualitative change in 5-lipoxygenase phenotype or genotype.

2. The method of Claim 1, wherein said quantitative or qualitative change in 5-lipoxygenase is a genetic polymorphism in the genomic sequence of 5-lipoxygenase.

3. The method of Claim 2, wherein said human 5-lipoxygenase allele comprises not more than 4 Sp1/Egr-1 binding sites in the promoter region of either chromosome.

4. The method of Claim 3, wherein said analyzing the genomic sequence comprises the steps of:

amplifying a region of the 5-lipoxygenase promoter from isolated genomic DNA to provide an amplified fragment;

detecting the presence of a polymorphic sequence in said amplified fragment.

5. The method of Claim 4, wherein said detecting step comprises hybridization with a probe specific for the sequence of said polymorphism.

6. A method of screening for biologically active agents that affect susceptibility to atherosclerosis, the method comprising:

combining a candidate biologically active agent with any one of:

(a) a 5-lipoxygenase polypeptide;

(b) a cell comprising a nucleic acid encoding a 5-lipoxygenase; or

(c) a non-human transgenic animal model for 5-lipoxygenase gene function comprising one of: (i) a knockout of a 5-lipoxygenase gene; (ii) an exogenous and stably transmitted 5-lipoxygenase gene; and

determining the effect of said agent susceptibility to atherosclerosis.

7. A method of treating atherosclerosis, the method comprising:

administering a patient an effective dose of a 5-lipoxygenase inhibitor.

1 / 9

FIG. 1A





FIG. 1B



2/9




FIG. 2A




FIG. 2B

3/9

FIG. 3A




FIG. 3D



FIG. 3B




FIG. 3E



FIG. 3C



α MOMA-2

FIG. 3F




α 5-LO

100X

4 / 9


FIG. 4A

FIG. 4B



5 / 9

FIG. 5



6 / 9

FIG. 6A






FIG. 6B



7/9

FIG. 7



8 / 9

FIG. 8A





FIG. 8B



9 / 9

Insulin Results - Dutch Population




FIG. 9

HOMA Results - Dutch Population




FIG. 10

SEQUENCE LISTING

<110> Margarete Mehrabian
Hooman Allayee
Aldons J. Lusic

<120> Identification of 5-Lipoxygenase as a
major gene contributing to atherosclerosis

<130> UCLA-004WO

<150> 60/335,244

<151> 2001-10-24

<160> 18

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2497

<212> DNA

<213> H. sapiens

<220>

<221> CDS

<222> (45)...(2069)

<223> Wild-type 5LO coding sequence

<400> 1

gggcgcgcgag gctccccgcc gctcgcgtgct ccccggcccg cgcc atg ccc tcc tac 56
Met Pro Ser Tyr
1

acg gtc acc gtg gcc act ggc agc cag tgg ttc gcc ggc act gac gac 104
Thr Val Thr Val Ala Thr Gly Ser Gln Trp Phe Ala Gly Thr Asp Asp
5 10 15 20

tac atc tac ctc agc ctc gtg ggc tcg gcg ggc tgc agc gag aag cac 152
Tyr Ile Tyr Leu Ser Leu Val Gly Ser Ala Gly Cys Ser Glu Lys His
25 30 35

ctg ctg gac aag ccc ttc tac aac gac ttc gag cgt ggc gcg gtg gat 200
Leu Leu Asp Lys Pro Phe Tyr Asn Asp Phe Glu Arg Gly Ala Val Asp
40 45 50

tca tac gac gtg act gtg gac gag gaa ctg ggc gag atc cag ctg gtc 248
Ser Tyr Asp Val Thr Val Asp Glu Glu Leu Gly Glu Ile Gln Leu Val
55 60 65

aga atc gag aag cgc aag tac tgg ctg aat gac gac tgg tac ctg aag 296
Arg Ile Glu Lys Arg Lys Tyr Trp Leu Asn Asp Asp Trp Tyr Leu Lys
70 75 80

tac atc acg ctg aag acg ccc cac ggg gac tac atc gag ttc ccc tgc 344
Tyr Ile Thr Leu Lys Thr Pro His Gly Asp Tyr Ile Glu Phe Pro Cys
85 90 95 100

tac cgc tgg atc acc ggc gat gtc gag gtt gtc ctg agg gat gga cgc 392
Tyr Arg Trp Ile Thr Gly Asp Val Glu Val Val Leu Arg Asp Gly Arg
105 110 115

gca aag ttg gcc cga gat gac caa att cac att ctc aag caa cac cga	440
Ala Lys Leu Ala Arg Asp Asp Gln Ile His Ile Leu Lys Gln His Arg	
120 125 130	
cgt aaa gaa ctg gaa aca cgg caa aaa caa tat cga tgg atg gag tgg	488
Arg Lys Glu Leu Glu Thr Arg Gln Lys Gln Tyr Arg Trp Met Glu Trp	
135 140 145	
aac cct ggc ttc ccc ttg agc atc gat gcc aaa tgc cac aag gat tta	536
Asn Pro Gly Phe Pro Leu Ser Ile Asp Ala Lys Cys His Lys Asp Leu	
150 155 160	
ccc cgt gat atc cag ttt gat agt gaa aaa gga gtg gac ttt gtt ctg	584
Pro Arg Asp Ile Gln Phe Asp Ser Glu Lys Gly Val Asp Phe Val Leu	
165 170 175 180	
aat tac tcc aaa gcg atg gag aac ctg ttc atc aac cgc ttc atg cac	632
Asn Tyr Ser Lys Ala Met Glu Asn Leu Phe Ile Asn Arg Phe Met His	
185 190 195	
atg ttc cag tct tct tgg aat gac ttc gcc gac ttt gag aaa atc ttt	680
Met Phe Gln Ser Ser Trp Asn Asp Phe Ala Asp Phe Glu Lys Ile Phe	
200 205 210	
gtc aag atc agc aac act att tct gag cgg gtc atg aat cac tgg cag	728
Val Lys Ile Ser Asn Thr Ile Ser Glu Arg Val Met Asn His Trp Gln	
215 220 225	
gaa gac ctg atg ttt ggc tac cag ttc ctg aat ggc tgc aac cct gtg	776
Glu Asp Leu Met Phe Gly Tyr Gln Phe Leu Asn Gly Cys Asn Pro Val	
230 235 240	
ttg atc cgg cgc tgc aca gag ctg ccc gag aag ctc ccg gtg acc acg	824
Leu Ile Arg Arg Cys Thr Glu Leu Pro Glu Lys Leu Pro Val Thr Thr	
245 250 255 260	
gag atg gta gag tgc agc ctg gag cgg cag ctc agc ttg gag cag gag	872
Glu Met Val Glu Cys Ser Leu Glu Arg Gln Leu Ser Leu Glu Gln Glu	
265 270 275	
gtc cag caa ggg aac att ttc atc gtg gac ttt gag ctg ctg gat ggc	920
Val Gln Gln Gly Asn Ile Phe Ile Val Asp Phe Glu Leu Leu Asp Gly	
280 285 290	
atc gat gcc aac aaa aca gac ccc tgc aca ctc cag ttc ctg gcc gct	968
Ile Asp Ala Asn Lys Thr Asp Pro Cys Thr Leu Gln Phe Leu Ala Ala	
295 300 305	
ccc atc tgc ttg ctg tat aag aac ctg gcc aac aag att gtc ccc att	1016
Pro Ile Cys Leu Leu Tyr Lys Asn Leu Ala Asn Lys Ile Val Pro Ile	
310 315 320	
gcc atc cag ctc aac caa atc ccg gga gat gag aac cct att ttc ctc	1064
Ala Ile Gln Leu Asn Gln Ile Pro Gly Asp Glu Asn Pro Ile Phe Leu	
325 330 335 340	
cct tcg gat gca aaa tac gac tgg ctt ttg gcc aaa atc tgg gtg cgt	1112
Pro Ser Asp Ala Lys Tyr Asp Trp Leu Leu Ala Lys Ile Trp Val Arg	
345 350 355	

tcc agt gac ttc cac gtc cac cag acc atc acc cac ctt ctg cga aca	1160
Ser Ser Asp Phe His Val His Gln Thr Ile Thr His Leu Leu Arg Thr	
360 365 370	
cat ctg gtg tct gag gtt ttt ggc att gca atg tac cgc cag ctg cct	1208
His Leu Val Ser Glu Val Phe Gly Ile Ala Met Tyr Arg Gln Leu Pro	
375 380 385	
gct gtg cac ccc att ttc aag ctg ctg gtg gca cac gtg aga ttc acc	1256
Ala Val His Pro Ile Phe Lys Leu Leu Val Ala His Val Arg Phe Thr	
390 395 400	
att gca atc aac acc aag gcc cgt gag cag ctc atc tgc gag tgt ggc	1304
Ile Ala Ile Asn Thr Lys Ala Arg Glu Gln Leu Ile Cys Glu Cys Gly	
405 410 415 420	
ctc ttt gac aag gcc aac gcc aca ggg ggc ggt ggg cac gtg cag atg	1352
Leu Phe Asp Lys Ala Asn Ala Thr Gly Gly Gly Gly His Val Gln Met	
425 430 435	
gtg cag agg gcc atg aag gac ctg acc tat gcc tcc ctg tgc ttt ccc	1400
Val Gln Arg Ala Met Lys Asp Leu Thr Tyr Ala Ser Leu Cys Phe Pro	
440 445 450	
gag gcc atc aag gcc cgg ggc atg gag agc aaa gaa gac atc ccc tac	1448
Glu Ala Ile Lys Ala Arg Gly Met Glu Ser Lys Glu Asp Ile Pro Tyr	
455 460 465	
tac ttc tac cgg gac gac ggg ctc ctg gtg tgg gaa gcc atc agg acg	1496
Tyr Phe Tyr Arg Asp Asp Gly Leu Leu Val Trp Glu Ala Ile Arg Thr	
470 475 480	
ttc acg gcc gag gtg gta gac atc tac tac gag ggc gac cag gtg gtg	1544
Phe Thr Ala Glu Val Val Asp Ile Tyr Tyr Glu Gly Asp Gln Val Val	
485 490 495 500	
gag gag gac ccg gag ctg cag gac ttc gtg aac gat gtc tac gtg tac	1592
Glu Glu Asp Pro Glu Leu Gln Asp Phe Val Asn Asp Val Tyr Val Tyr	
505 510 515	
ggc atg cgg ggc cgc aag tcc tca ggc ttc ccc aag tcg gtc aag agc	1640
Gly Met Arg Gly Arg Lys Ser Ser Gly Phe Pro Lys Ser Val Lys Ser	
520 525 530	
cgg gag cag ctg tcg gag tac ctg acc gtg gtg atc ttc acc gcc tcc	1688
Arg Glu Gln Leu Ser Glu Tyr Leu Thr Val Val Ile Phe Thr Ala Ser	
535 540 545	
gcc cag cac gcc gcg gtc aac ttc ggc cag tac gac tgg tgc tcc tgg	1736
Ala Gln His Ala Ala Val Asn Phe Gly Gln Tyr Asp Trp Cys Ser Trp	
550 555 560	
atc ccc aat gcg ccc cca acc atg cga gcc ccg cca ccg act gcc aag	1784
Ile Pro Asn Ala Pro Pro Thr Met Arg Ala Pro Pro Thr Ala Lys	
565 570 575 580	
ggc gtg gtg acc att gag cag atc gtg gac acg ctg ccc gac cgc ggc	1832
Gly Val Val Thr Ile Glu Gln Ile Val Asp Thr Leu Pro Asp Arg Gly	
585 590 595	

cgc tcc tgc tgg cat ctg ggt gca gtg tgg gcg ctg agc cag ttc cag	1880
Arg Ser Cys Trp His Leu Gly Ala Val Trp Ala Leu Ser Gln Phe Gln	
600 605 610	
 gaa aac gag ctg ttc ctg ggc atg tac cca gaa gag cat ttt atc gag	1928
Glu Asn Glu Leu Phe Leu Gly Met Tyr Pro Glu Glu His Phe Ile Glu	
615 620 625	
 aag cct gtg aag gaa gcc atg gcc cga ttc cgc aag aac ctc gag gcc	1976
Lys Pro Val Lys Glu Ala Met Ala Arg Phe Arg Lys Asn Leu Glu Ala	
630 635 640	
 att gtc agc gtg att gct gag cgc aac aag aag aag cag ctg cca tat	2024
Ile Val Ser Val Ile Ala Glu Arg Asn Lys Lys Lys Gln Leu Pro Tyr	
645 650 655 660	
 tac tac ttg tcc cca gac cgg att ccg aac agt gtg gcc atc tga	2069
Tyr Tyr Leu Ser Pro Asp Arg Ile Pro Asn Ser Val Ala Ile *	
665 670	
 gcacactgcc agtctcactg tgggaaggcc agctgcccc gccagatgga ctccagcctg	2129
cctggcaggc tgtctggcca ggcctcttgg cagtcacatc tcttcctccg aggccagtac	2189
ctttccattt attctttgat cttcagggaa ctgcatagat tgtatcaaag tgtaaacacc	2249
atagggaccc attctacaca gagcaggact gcacaggcgt cctgtccaca ccagctcag	2309
catttccaca ccaagcagca acagcaaadc acgaccactg atagatgtct attcttgttg	2369
gagacatggg atgattattt tctgttctat ttgtgcttag tccaattcct tgcacatagt	2429
aggtacccaa ttcaattact attgaatgaa ttaagaattg gttgccataa aaataaatca	2489
gttcattt	2497
 <210> 2	
<211> 20	
<212> DNA	
<213> M. musculus	
 <400> 2	
atcgccttct tgacgagttc	20
 <210> 3	
<211> 21	
<212> DNA	
<213> M. musculus	
 <400> 3	
gcaggaagtg gctactgttg a	21
 <210> 4	
<211> 21	
<212> DNA	
<213> M. musculus	
 <400> 4	
tgcaaccag tactcatcaa g	21
 <210> 5	
<211> 25	
<212> DNA	
<213> M. musculus	
 <400> 5	
acccaagac gtgctcccag gatga	25
 <210> 6	

<211> 24
<212> DNA
<213> M. musculus

<400> 6
cgcagtgcctc ctcatctgac ttgt 24

<210> 7
<211> 25
<212> DNA
<213> M. musculus

<400> 7
aggatctcgt cgtgacccat ggcga 25

<210> 8
<211> 26
<212> DNA
<213> M. musculus

<400> 8
gagcggcgat accgtaaagc acgagg 26

<210> 9
<211> 27
<212> DNA
<213> M. musculus

<400> 9
atgccctatg ccctcctaca ctgtcac 27

<210> 10
<211> 21
<212> DNA
<213> M. musculus

<400> 10
ccactccatc catctatact g 21

<210> 11
<211> 22
<212> DNA
<213> M. musculus

<400> 11
gcagcacaga cgtaaagaac tg 22

<210> 12
<211> 21
<212> DNA
<213> M. musculus

<400> 12
gaggaagtca ctggaacgca c 21

<210> 13
<211> 22
<212> DNA
<213> M. musculus

<400> 13
ctacggattc aaagtacgac tg 22

6

tac tgg ctc cat gat gac tgg tac ctg aag tac atc aca ctg aag aca Tyr Trp Leu His Asp Asp Trp Tyr Leu Lys Tyr Ile Thr Leu Lys Thr 75 80 85 90	352
ccc cac ggg gac tac atc gag ttc cca tgt tac cgc tgg atc aca ggc Pro His Gly Asp Tyr Ile Glu Phe Pro Cys Tyr Arg Trp Ile Thr Gly 95 100 105	400
gag ggc gag att gtc ctg agg gat gga cgt gca aaa ttg gcc cga gat Glu Gly Glu Ile Val Leu Arg Asp Gly Arg Ala Lys Leu Ala Arg Asp 110 115 120	448
gac caa att cac atc ctc aag cag cac aga cgt aaa gaa ctg gag gca Asp Gln Ile His Ile Leu Lys Gln His Arg Arg Lys Glu Leu Glu Ala 125 130 135	496
cgg caa aaa cag tat cga tgg atg gag tgg aac ccc ggc ttc cct ttg Arg Gln Lys Gln Tyr Arg Trp Met Glu Trp Asn Pro Gly Phe Pro Leu 140 145 150	544
agt atc gat gcc aaa tgc cac aag gat ctg ccc cga gat atc cag ttt Ser Ile Asp Ala Lys Cys His Lys Asp Leu Pro Arg Asp Ile Gln Phe 155 160 165 170	592
gat agt gaa aaa gga gtg gac ttt gtt ctg aac tac tca aaa gcg atg Asp Ser Glu Lys Gly Val Asp Phe Val Leu Asn Tyr Ser Lys Ala Met 175 180 185	640
gag aac ctg ttc atc aac cgc ttc atg cac atg ttc cag tct tcc tgg Glu Asn Leu Phe Ile Asn Arg Phe Met His Met Phe Gln Ser Ser Trp 190 195 200	688
cac gac ttt gct gac ttt gag aaa atc ttc gtc aaa atc agc aac act His Asp Phe Ala Asp Phe Glu Lys Ile Phe Val Lys Ile Ser Asn Thr 205 210 215	736
ata tct gag cga gtc aag aac cac tgg cag gaa gac ctc atg ttt ggc Ile Ser Glu Arg Val Lys Asn His Trp Gln Glu Asp Leu Met Phe Gly 220 225 230	784
tac cag ttc ctg aat ggc tgc aac cca gta ctc atc aag cgc tgc aca Tyr Gln Phe Leu Asn Gly Cys Asn Pro Val Leu Ile Lys Arg Cys Thr 235 240 245 250	832
gcg ttg ccc ccg aag ctc cca gtg acc aca gag atg gtg gag tgc agc Ala Leu Pro Pro Lys Leu Pro Val Thr Thr Glu Met Val Glu Cys Ser 255 260 265	880
cta gag cgg cag ctc agt tta gaa cag gaa gta cag gaa ggg aac att Leu Glu Arg Gln Leu Ser Leu Glu Gln Glu Val Gln Glu Gly Asn Ile 270 275 280	928
ttc atc gtt gat tac gag cta ctg gat ggc atc gat gct aac aaa act Phe Ile Val Asp Tyr Glu Leu Leu Asp Gly Ile Asp Ala Asn Lys Thr 285 290 295	976
gac ccc tgt aca cac cag ttc ctg gct gcc ccc atc tgc ctg cta tat Asp Pro Cys Thr His Gln Phe Leu Ala Ala Pro Ile Cys Leu Leu Tyr 300 305 310	1024

aag aac cta gcc aac aag att gtt ccc att gcc atc cag ctc aac caa Lys Asn Leu Ala Asn Lys Ile Val Pro Ile Ala Ile Gln Leu Asn Gln 315 320 325 330	1072
acc cct gga gag agt aac cca atc ttc ctc cct acg gat tca aag tac Thr Pro Gly Glu Ser Asn Pro Ile Phe Leu Pro Thr Asp Ser Lys Tyr 335 340 345	1120
gac tgg ctt ttg gcc aaa atc tgg gtg cgt tcc agt gac ttc cac gtc Asp Trp Leu Leu Ala Lys Ile Trp Val Arg Ser Ser Asp Phe His Val 350 355 360	1168
cat caa acg atc acc cac ctt ctg cgc acg cat ctg gtg tct gag gtg His Gln Thr Ile Thr His Leu Leu Arg Thr His Leu Val Ser Glu Val 365 370 375	1216
ttt ggt atc gcc atg tac cgc cag ctg cct gct gtg cat ccc ctt ttc Phe Gly Ile Ala Met Tyr Arg Gln Leu Pro Ala Val His Pro Leu Phe 380 385 390	1264
aag ctg ctg gta gcc cat gtg agg ttc acc att gct atc aac act aag Lys Leu Leu Val Ala His Val Arg Phe Thr Ile Ala Ile Asn Thr Lys 395 400 405 410	1312
gcc cgg gaa cag ctt atc tgc gag tat ggc ctt ttt gac aag gcc aat Ala Arg Glu Gln Leu Ile Cys Glu Tyr Gly Leu Phe Asp Lys Ala Asn 415 420 425	1360
gcc acc ggg ggt gga ggg cac gtg cag atg gtg cag agg gct gtc cag Ala Thr Gly Gly Gly His Val Gln Met Val Gln Arg Ala Val Gln 430 435 440	1408
gat ctg acc tat tcc tcc ctg tgt ttc ccg gag gcc atc aag gcc cgg Asp Leu Thr Tyr Ser Ser Leu Cys Phe Pro Glu Ala Ile Lys Ala Arg 445 450 455	1456
ggc atg gac agc acg gaa gac atc ccc ttc tac ttc tat cgt gat gat Gly Met Asp Ser Thr Glu Asp Ile Pro Phe Tyr Phe Tyr Arg Asp Asp 460 465 470	1504
gga ctg ctc gtg tgg gag gct atc cag tgc ttc aca atg gag gtg gtg Gly Leu Leu Val Trp Glu Ala Ile Gln Ser Phe Thr Met Glu Val Val 475 480 485 490	1552
agc atc tac tat gag aac gac cag gtg gtg gag gag gac cag gaa ctg Ser Ile Tyr Tyr Glu Asn Asp Gln Val Val Glu Glu Asp Gln Glu Leu 495 500 505	1600
cag gac ttc gtg aag gat gtt tac gtg tac ggc atg cgg ggc aaa aag Gln Asp Phe Val Lys Asp Val Tyr Val Tyr Gly Met Arg Gly Lys Lys 510 515 520	1648
gcc tca ggt ttc ccc aag tcc atc aag agc agg gag aag ctg tcc gag Ala Ser Gly Phe Pro Lys Ser Ile Lys Ser Arg Glu Lys Leu Ser Glu 525 530 535	1696
tac ctg acg gtg gtg atc ttc acg gcc tct gcc cag cat gca gct gta Tyr Leu Thr Val Val Ile Phe Thr Ala Ser Ala Gln His Ala Ala Val 540 545 550	1744

```

aac ttc ggc cag tat gac tgg tgc tcc tgg atc ccc aac gct cct cca      1792
Asn Phe Gly Gln Tyr Asp Trp Cys Ser Trp Ile Pro Asn Ala Pro Pro
555                               560                               565                               570

act atg cgg gcc cca cca ccc acg gcc aag ggt gtg gtc acc atc gag      1840
Thr Met Arg Ala Pro Pro Pro Thr Ala Lys Gly Val Val Thr Ile Glu
                    575                               580                               585

cag atc gtg gat act cta cca gac cgt ggc cga tca tgt tgg cat cta      1888
Gln Ile Val Asp Thr Leu Pro Asp Arg Gly Arg Ser Cys Trp His Leu
                    590                               595                               600

ggt gca gtg tgg gcc ttg agc cag ttt caa gaa aat gag ctg ttt cta      1936
Gly Ala Val Trp Ala Leu Ser Gln Phe Gln Glu Asn Glu Leu Phe Leu
                    605                               610                               615

ggc atg tac cca gag gag cat ttc att gag aag cca gtg aag gaa gcc      1984
Gly Met Tyr Pro Glu Glu His Phe Ile Glu Lys Pro Val Lys Glu Ala
                    620                               625                               630

atg atc cga ttc cgc aag aac ctg gag gcc gtc atc agc gtg atc gcc      2032
Met Ile Arg Phe Arg Lys Asn Leu Glu Ala Val Ile Ser Val Ile Ala
                    635                               640                               645                               650

gag cgc aat aag aac aaa aag ctc ccc tac tac tac ctg tca cca gac      2080
Glu Arg Asn Lys Asn Lys Lys Leu Pro Tyr Tyr Tyr Leu Ser Pro Asp
                    655                               660                               665

agg att ccc aac agt gta gcc atc taa      2107
Arg Ile Pro Asn Ser Val Ala Ile *
                    670

```

<210> 18

<211> 2107

<212> DNA

<213> M. musculus

<220>

<221> CDS

<222> (83)...(2107)

<223> B6 strain coding sequence

<400> 18

```

agggtcaaga agttggtggg ctgccacgcc gagcttcgcg ggctcctgct cccacaccag      60
cagcactcac ttgcccgag tc atg ccc tcc tac acg gtc acc gtg gcc acc      112
                               Met Pro Ser Tyr Thr Val Thr Val Ala Thr
                               1                               5                               10

ggc agc cag tgg ttc gcg ggc acc gac gac tac atc tac ctc agc ctc      160
Gly Ser Gln Trp Phe Ala Gly Thr Asp Asp Tyr Ile Tyr Leu Ser Leu
                               15                               20                               25

att ggc tct gcg ggc tgt agc gag aag cat ctg ctg gac aag gca ttc      208
Ile Gly Ser Ala Gly Cys Ser Glu Lys His Leu Leu Asp Lys Ala Phe
                               30                               35                               40

tac aat gac ttc gaa cgg ggc gcg gtg gac tcc tac gat gtc acc gtg      256
Tyr Asn Asp Phe Glu Arg Gly Ala Val Asp Ser Tyr Asp Val Thr Val
                               45                               50                               55

```

gat gag gag ctg ggc gag atc tac cta gtc aaa att gag aag cgc aaa Asp Glu Glu Leu Gly Glu Ile Tyr Leu Val Lys Ile Glu Lys Arg Lys 60 65 70	304
tac tgg ctc cat gat gac tgg tac ctg aag tac atc aca ctg aag aca Tyr Trp Leu His Asp Asp Trp Tyr Leu Lys Tyr Ile Thr Leu Lys Thr 75 80 85 90	352
ccc cac ggg gac tac atc gag ttc cca tgt tac cgc tgg atc aca ggc Pro His Gly Asp Tyr Ile Glu Phe Pro Cys Tyr Arg Trp Ile Thr Gly 95 100 105	400
gag ggc gag att gtc ctg agg gat gga cgt gca aaa ttg gcc cga gat Glu Gly Glu Ile Val Leu Arg Asp Gly Arg Ala Lys Leu Ala Arg Asp 110 115 120	448
gac caa att cac atc ctc aag cag cac aga cgt aaa gaa ctg gag gca Asp Gln Ile His Ile Leu Lys Gln His Arg Arg Lys Glu Leu Glu Ala 125 130 135	496
cgg caa aaa cag tat aga tgg atg gag tgg aac ccc ggc ttc cct ttg Arg Gln Lys Gln Tyr Arg Trp Met Glu Trp Asn Pro Gly Phe Pro Leu 140 145 150	544
agt att gat gcc aaa tgc cac aag gat ctg ccc cga gat atc cag ttt Ser Ile Asp Ala Lys Cys His Lys Asp Leu Pro Arg Asp Ile Gln Phe 155 160 165 170	592
gat agt gaa aaa gga gtg gac ttt gtt ctg aac tac tca aaa gcg atg Asp Ser Glu Lys Gly Val Asp Phe Val Leu Asn Tyr Ser Lys Ala Met 175 180 185	640
gag aac ctg ttc atc aac cgc ttc atg cac atg ttc cag tct tcc tgg Glu Asn Leu Phe Ile Asn Arg Phe Met His Met Phe Gln Ser Ser Trp 190 195 200	688
cac gac ttt gct gac ttt gag aaa atc ttc gtc aaa atc agc aac act His Asp Phe Ala Asp Phe Glu Lys Ile Phe Val Lys Ile Ser Asn Thr 205 210 215	736
ata tct gag cga gtc aag aac cac tgg cag gaa gac ctc atg ttt ggc Ile Ser Glu Arg Val Lys Asn His Trp Gln Glu Asp Leu Met Phe Gly 220 225 230	784
tac cag ttc ctg aat ggc tgc aac cca gta ctc atc aag cgc tgc aca Tyr Gln Phe Leu Asn Gly Cys Asn Pro Val Leu Ile Lys Arg Cys Thr 235 240 245 250	832
gcg ttg ccc ccg aag ctc cca gtg acc aca gag atg gtg gag tgc agc Ala Leu Pro Pro Lys Leu Pro Val Thr Thr Glu Met Val Glu Cys Ser 255 260 265	880
cta gag cgg cag ctc agt tta gaa cag gaa gta cag gaa ggg aac att Leu Glu Arg Gln Leu Ser Leu Glu Gln Glu Val Gln Glu Gly Asn Ile 270 275 280	928
ttc atc gtt gat tac gag cta ctg gat ggc atc gat gct aac aaa act Phe Ile Val Asp Tyr Glu Leu Leu Asp Gly Ile Asp Ala Asn Lys Thr 285 290 295	976

gac ccc tgt aca cac cag ttc ctg gct gcc ccc atc tgc ctg cta tat	1024
Asp Pro Cys Thr His Gln Phe Leu Ala Ala Pro Ile Cys Leu Leu Tyr	
300 305 310	
aag aac cta gcc aac aag att gtt ccc att gcc atc cag ctc aac caa	1072
Lys Asn Leu Ala Asn Lys Ile Val Pro Ile Ala Ile Gln Leu Asn Gln	
315 320 325 330	
acc cct gga gag agt aac cca atc ttc ctc cct acg gat tca aag tac	1120
Thr Pro Gly Glu Ser Asn Pro Ile Phe Leu Pro Thr Asp Ser Lys Tyr	
335 340 345	
gac tgg ctt ttg gcc aaa atc tgg gtg cgt tcc agt gac ttc cac gtc	1168
Asp Trp Leu Leu Ala Lys Ile Trp Val Arg Ser Ser Asp Phe His Val	
350 355 360	
cat caa acg atc acc cac ctt ctg cgc acg cat ctg gtg tct gag gtg	1216
His Gln Thr Ile Thr His Leu Leu Arg Thr His Leu Val Ser Glu Val	
365 370 375	
ttt ggt atc gcc atg tac cgc cag ctg cct gct gtg cat ccc ctt ttc	1264
Phe Gly Ile Ala Met Tyr Arg Gln Leu Pro Ala Val His Pro Leu Phe	
380 385 390	
aag ctg ctg gta gcc cat gtg agg ttc acc att gct atc aac act aag	1312
Lys Leu Leu Val Ala His Val Arg Phe Thr Ile Ala Ile Asn Thr Lys	
395 400 405 410	
gcc cgg gaa cag ctt atc tgc gag tat ggc ctt ttt gac aag gcc aat	1360
Ala Arg Glu Gln Leu Ile Cys Glu Tyr Gly Leu Phe Asp Lys Ala Asn	
415 420 425	
gcc acc ggg ggt gga ggg cac gtg cag atg gtg cag agg gct gtc cag	1408
Ala Thr Gly Gly Gly Gly His Val Gln Met Val Gln Arg Ala Val Gln	
430 435 440	
gat ctg acc tat tcc tcc ctg tgt ttc ccg gag gcc atc aag gcc cgg	1456
Asp Leu Thr Tyr Ser Ser Leu Cys Phe Pro Glu Ala Ile Lys Ala Arg	
445 450 455	
ggc atg gac agc acg gaa gac atc ccc ttc tac ttc tat cgt gat gat	1504
Gly Met Asp Ser Thr Glu Asp Ile Pro Phe Tyr Phe Tyr Arg Asp Asp	
460 465 470	
gga ctg ctc gtg tgg gag gct atc cag tcg ttc aca atg gag gtg gtg	1552
Gly Leu Leu Val Trp Glu Ala Ile Gln Ser Phe Thr Met Glu Val Val	
475 480 485 490	
agc atc tac tat gag aac gac cag gtg gtg gag gag gac cag gaa ctg	1600
Ser Ile Tyr Tyr Glu Asn Asp Gln Val Val Glu Glu Asp Gln Glu Leu	
495 500 505	
cag gac ttc gtg aag gat gtt tac gtg tac ggc atg cgg ggc aaa aag	1648
Gln Asp Phe Val Lys Asp Val Tyr Val Tyr Gly Met Arg Gly Lys Lys	
510 515 520	
gcc tca ggt ttc ccc aag tcc atc aag agc agg gag aag ctg tcc gag	1696
Ala Ser Gly Phe Pro Lys Ser Ile Lys Ser Arg Glu Lys Leu Ser Glu	
525 530 535	

tac	ctg	acg	gtg	gtg	atc	ttc	acg	gcc	tct	gcc	cag	cat	gca	gct	gta	1744
Tyr	Leu	Thr	Val	Val	Ile	Phe	Thr	Ala	Ser	Ala	Gln	His	Ala	Ala	Val	
540						545					550					
aac	ttc	ggc	cag	tat	gac	tgg	tgc	tcc	tgg	atc	ccc	aac	gct	cct	cca	1792
Asn	Phe	Gly	Gln	Tyr	Asp	Trp	Cys	Ser	Trp	Ile	Pro	Asn	Ala	Pro	Pro	
555					560					565					570	
act	atg	cgg	gcc	cca	cca	ccc	acg	gcc	aag	ggt	gtg	gtc	acc	atc	gag	1840
Thr	Met	Arg	Ala	Pro	Pro	Pro	Thr	Ala	Lys	Gly	Val	Val	Thr	Ile	Glu	
				575					580					585		
cag	atc	gtg	gat	act	cta	cca	gac	cgt	ggc	cga	tca	tgt	tgg	cat	cta	1888
Gln	Ile	Val	Asp	Thr	Leu	Pro	Asp	Arg	Gly	Arg	Ser	Cys	Trp	His	Leu	
			590					595					600			
ggt	gca	gtg	tgg	gcc	ttg	agc	cag	ttt	caa	gaa	aat	gag	ctg	ttt	cta	1936
Gly	Ala	Val	Trp	Ala	Leu	Ser	Gln	Phe	Gln	Glu	Asn	Glu	Leu	Phe	Leu	
		605					610					615				
ggc	atg	tac	cca	gag	gag	cat	ttc	att	gag	aag	cca	gtg	aag	gaa	gcc	1984
Gly	Met	Tyr	Pro	Glu	Glu	His	Phe	Ile	Glu	Lys	Pro	Val	Lys	Glu	Ala	
		620				625					630					
atg	atc	cga	ttc	cgc	aag	aac	ctg	gag	gcc	atc	gtc	agc	gtg	atc	gcc	2032
Met	Ile	Arg	Phe	Arg	Lys	Asn	Leu	Glu	Ala	Ile	Val	Ser	Val	Ile	Ala	
635					640					645					650	
gag	cgc	aat	aag	aac	aaa	aag	ctc	ccc	tac	tac	tac	ctg	tca	cca	gac	2080
Glu	Arg	Asn	Lys	Asn	Lys	Lys	Leu	Pro	Tyr	Tyr	Tyr	Leu	Ser	Pro	Asp	
				655					660					665		
agg	att	ccc	aac	agt	gta	gcc	atc	taa								2107
Arg	Ile	Pro	Asn	Ser	Val	Ala	Ile	*								
				670												

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035670 A3

- (51) International Patent Classification⁷: **C12Q 1/68**
- (21) International Application Number: **PCT/US02/34208**
- (22) International Filing Date: 24 October 2002 (24.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/335,244 24 October 2001 (24.10.2001) US
- (71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MEHRABIAN, Margarete** [US/US]; University of California Los Angeles, Department of Medicine, 3-222 MRL, Los Angeles, CA 90095 (US). **ALLAYEE, Hooman** [US/US]; Department of Human Genetics, Gonda Genetics Research Center, Room 6524, UCLA School of Medicine, 695 Charles young Dr. South, Los Angeles, CA 90095 (US). **LUSIS, Aldons, J.** [US/US]; University of California Los Angeles, Department of Medicine, 47-123 CHS, Los Angeles, CA 90095-1679 (US).
- (74) Agent: **SHERWOOD, Pamela, J.**; Bozicevic, Field & Francis LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- (88) Date of publication of the international search report:
10 July 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF 5-LIPOXYGENASE AS A MAJOR GENE CONTRIBUTING TO ATHEROSCLEROSIS

(57) Abstract: 5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR^{-/-} background, have dramatically reduced atherosclerosis as compared to control LDLR₊ mice. In a genetic epidemiologic study, it is found that a common 5-LO polymorphism is strongly associated with carotid artery intima-media thickness (IMT). These results indicate that 5-LO is a major contributor to atherogenesis in animal models, and in atherosclerosis susceptibility in humans.

WO 03/035670 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/34208

A. CLASSIFICATION OF SUBJECT MATTER												
IPC(7) : C12Q 1/68 US CL : 435/6												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X,P — Y,P	MEHRABIAN. M. et al. Identification of 5-Lipoxygenase as a major Gene Contributing to Atherosclerosis Susceptibility in Mice. Circulation Research. 2002, Vol. 91, pages 120-126, see whole document.	1-5 — 6, 7										
A	IN, K.H. et al. Naturally Occuring Mutations in the Human 5-Lipoxygenase Gene Promoter That Modify Transcription Factor Binding and Reporter Gene Transcription. Journal of Clinical Investigation. March 1997, Vol. 99, pages 1130-1137, see whole document.	1-7										
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 08 March 2003 (08.03.2003)		Date of mailing of the international search report 18 APR 2003										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer <i>Jehanne E. Souza</i> Jehanne E Souza Telephone No. 703-308-0196										

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US02/34208

Continuation of B. FIELDS SEARCHED Item 3:

Medline, Caplus, East

search terms: 5 lipoxygenase, atherosclerosis, mutation, polymorphism, expression, protein

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)